Trends & Forecasts

Intellectual property issues have suffocated many industry collaborations. And though IP is clearly valuable to pharma companies, there is also value in learning to let go.

A US coalition seeks lower prices for US prescription drugs, but could their proposals undermine the competitive market?

Abbott, Abbvie and Sanofi all make separate merger announcements – on the same day

What’s the best way to present a health resource? Apparently, ease of use trumps all other factors

Are you a budding biotech or pharma startup? “The Hive” could be your chance to showcase your work

Sitting Down With... Ann Hayes, Owner, The Ann Hayes Consultancy, Stevenage, UK.

Welcome to The Power List 2016

Innovation is increasingly coming from small biotechs, but such companies rely on external funding to develop the compounds. A solid regulatory strategy is essential to convince investors to fund the further development.

The pharmaceutical industry receives its fair share of both praise and scorn. Behind the politics, the hard work and impressive achievements of legions of industry researchers often go unnoticed.

Sir Andrew Witty seeks to cement his legacy as GSK addresses patents and medicines access in the developing world